scholarly journals Using Graphene-Based Biosensors to Detect Dopamine for Efficient Parkinson’s Disease Diagnostics

Biosensors ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 433
Author(s):  
Małgorzata Kujawska ◽  
Sheetal K. Bhardwaj ◽  
Yogendra Kumar Mishra ◽  
Ajeet Kaushik
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
High Performance ◽  
Limit Of Detection ◽  
Point Of Care ◽  
Electrochemical Sensing ◽  
Technical Performance ◽  
Disease Diagnostics ◽  
Nigrostriatal Neurons ◽  
Interference Studies

Parkinson’s disease (PD) is a neurodegenerative disease in which the neurotransmitter dopamine (DA) depletes due to the progressive loss of nigrostriatal neurons. Therefore, DA measurement might be a useful diagnostic tool for targeting the early stages of PD, as well as helping to optimize DA replacement therapy. Moreover, DA sensing appears to be a useful analytical tool in complex biological systems in PD studies. To support the feasibility of this concept, this mini-review explores the currently developed graphene-based biosensors dedicated to DA detection. We discuss various graphene modifications designed for high-performance DA sensing electrodes alongside their analytical performances and interference studies, which we listed based on their limit of detection in biological samples. Moreover, graphene-based biosensors for optical DA detection are also presented herein. Regarding clinical relevance, we explored the development trends of graphene-based electrochemical sensing of DA as they relate to point-of-care testing suitable for the site-of-location diagnostics needed for personalized PD management. In this field, the biosensors are developed into smartphone-connected systems for intelligent disease management. However, we highlighted that the focus should be on the clinical utility rather than analytical and technical performance.

scholarly journals Gold-nanourchin complexed silicon dioxide-probe on gap-fingered interdigitated electrode surface for Parkinson’s Disease determination by current–volt measurement

2021 ◽  
Vol 11 ◽  
pp. 184798042098735
Author(s):  
Xiaohong Li ◽  
Wei Shi ◽  
Wenyan Zhang ◽  
Weiyao Chen ◽  
Dan Cao ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Silicon Dioxide ◽  
Limit Of Detection ◽  
Detection System ◽  
Interdigitated Electrode ◽  
Limit Of Quantification ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Detection Range

Parkinson’s disease (PD) is a nervous disorder, affects physical movement, and leads to difficulty in balancing, walking, and coordination. A novel sensor is mandatory to determine PD and monitor the progress of the treatment. Neurofilament light chain (NfL) has been recognized as a good biomarker for PD and also helps to distinguish between PD and atypical PD syndromes. Immunosensor was generated by current–volt measurement on gap-fingered interdigitated electrode with silicon dioxide surface to determine NfL level. To enhance the detection, anti-NfL antibody was complexed with gold-nanourchin and immobilized on the sensing electrode. The current–volt response was gradually increased at the linear detection range from 100 fM to 1 nM. Limit of detection and sensitivity were 100 fM with the signal-to-noise ratio at n = 3 on a linear curve ( y = 0.081 x + 1.593; R 2 = 0.9983). Limit of quantification falls at 1 pM and high performance of the sensor was demonstrated by discriminating against other neurogenerative disease markers, in addition, it was reproducible even in serum-spiked samples. This method of detection system aids to measure the level of NfL and leads to determine the condition with PD.

Core-shell Cu@C@ZIF-8 composite: a high-performance electrode material for electrochemical sensing of nitrite with high selectivity and sensitivity

2021 ◽  
Author(s):  
Feng Gao ◽  
Xiaolong Tu ◽  
Yongfang Yu ◽  
Yansha Gao ◽  
Jin Zou ◽  
...  
Keyword(s):  
High Performance ◽  
High Selectivity ◽  
Limit Of Detection ◽  
Metal Organic Framework ◽  
High Sensitivity ◽  
Electrochemical Sensing ◽  
Core Shell ◽  
Zeolitic Imidazolate Framework ◽  
Sensing Platform ◽  
The Difference

Abstract Herein, an efficient electrochemical sensing platform is proposed for selective and sensitive detection of nitrite on the basis of Cu@C@Zeolitic imidazolate framework-8 (Cu@C@ZIF-8) heterostructure. Core-shell Cu@C@ZIF-8 composite was synthesized by pyrolysis of Cu-metal-organic framework@ZIF-8 (Cu-MOF@ZIF-8) in Ar atmosphere on account of the difference of thermal stability between Cu-MOF and ZIF-8. For the sensing system of Cu@C@ZIF-8, ZIF-8 with proper pore size allows nitrite diffuse through the shell, while big molecules cannot, which ensures high selectivity of the sensor. On the other hand, Cu@C as electrocatalyst promotes the oxidation of nitrite, thereby resulting high sensitivity of the sensor. Accordingly, the Cu@C@ZIF-8 based sensor presents excellent performance for nitrite detection, which achieves a wide linear response range of 0.1 µM to 300.0 µM, and a low limit of detection (LOD) of 0.033 µM. In addition, the Cu@C@ZIF-8 sensor possesses excellent stability and reproducibility, and was employed to quantify nitrite in sausage samples with recoveries of 95.45-104.80%.

scholarly journals Severe and regionally-widespread increases in tissue urea in the human brain represent a novel finding of pathogenic potential in Parkinson’s disease dementia

2021 ◽  
Author(s):  
Melissa Scholefield ◽  
Stephanie J. Church ◽  
Jingshu Xu ◽  
Stefano Patassini ◽  
Federico Roncaroli ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
High Performance ◽  
Current Knowledge ◽  
Neuronal Loss ◽  
Middle Temporal Gyrus ◽  
Parkinson’S Disease Dementia ◽  
Pathogenic Potential ◽  
Age Related ◽  
Liquid Chromatography Tandem Mass

Abstract Background: Widespread elevations in brain urea have, in recent years, been reported in certain types of age-related dementia, notably Alzheimer’s disease (AD) and Huntington’s disease (HD). Urea increases in these diseases are substantive, and approximate in magnitude to levels present in uraemic encephalopathy. In AD and HD, elevated urea levels occur across the entire brain, and not only in regions heavily affected by neurodegeneration. However, measurements of brain urea have not hitherto been reported in Parkinson’s disease dementia (PDD), a condition defined by changes in thinking and behaviour in someone with a diagnosis of Parkinson's disease, which shares neuropathological and symptomatic overlap with both AD and HD. This study aims to address this gap in the current knowledge of PDD.Methods: Here we report measurements of tissue urea from nine neuropathologically-confirmed regions of the brain in PDD and post-mortem-delay-matched controls, in regions that included the cerebellum, motor cortex, sensory cortex, hippocampus, substantia nigra, middle temporal gyrus, medulla oblongata, cingulate gyrus, and pons, by applying ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Case-control differences were determined using multiple t-tests followed by correction with 10% false discovery rate.Results: We found urea concentrations to be substantively elevated in all nine regions, the average increase being 3-4-fold. Urea concentrations were remarkably consistent across regions in both cases and controls, with no clear distinction between regions heavily affected by neuronal loss in PDD compared to less severely affected areas. These urea elevations mirror those found in uraemic encephalopathy, where equivalent levels are generally considered to be pathogenic. These urea elevations also reflect those previously reported in AD and HD. Conclusions: Increased urea is a widespread metabolic perturbation in brain metabolism common to PDD, AD, and HD, at levels equal to those seen in uremic encephalopathy. This presents a novel pathogenic mechanism in PDD, which is shared with two other neurodegenerative diseases.

scholarly journals Relationship between serum homocysteine level and cognitive impairment in patients with Parkinson‘s disease

Pteridines ◽  
2019 ◽  
Vol 30 (1) ◽  
pp. 177-182
Author(s):  
Xuejuan Liu ◽  
Tong Dong ◽  
Yi Zhang ◽  
Yumei Zhao ◽  
Jingwen Yang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
High Performance ◽  
Serum Folate ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serum Homocysteine ◽  
Folate And Vitamin B12 ◽  
Sensitivity Specificity ◽  
Clinical Characteristic

Abstract OBJECTIVE To investigate the correlation between serum homocysteine (Hcy) and cognitive impairment (CI) in patients with Parkinson’s disease (PD). METHODS Eighty-one PD patients were prospectively recruited in this study from Feb 2015 to Jan 2018 in Gansu Provincial Hospital. Of the subjects, 41 were diagnosed with cognitive impairment (PD-CI) vs. the 40 others without PD (PDN). The clinical characteristic and demographic features were recorded for the two groups. The serum Hcy, folate and vitamin B12 (VitB12) were examined by high-performance liquid chromatography (HPLC) and enzyme-linked immunosorbent assay (ELISA). RESULTS The serum Hcy, folate, VitB12 concentration were 21.7±6.2 (μmol/L), 9.2±3.7 (ng/mL), 354.1±123.5 (pg/mL) for PD-CI group and 14.1±5.7 (μmol/L), 12.4±4.5 (ng/mL), 378.7±128.2 (pg/mL) for PDN group respectively. The serum level of Hcy in PD-CI group was significantly higher than that of PDN group (p<0.05), serum folate was significantly lower than PDN group (p<0.05). The diagnostic sensitivity, specificity and AUC were 77.5% (95%CI:61.6%-89.2%), 78.1% (95%CI:62.4%-89.4%), 0.82 (95%CI:0.73-0.91) for serum Hcy and 72.5% (95%CI:56.1%-85.4%), 63.4% (95%CI:46.9%-77.9%), 0.71(95%CI:0060-0.83) for serum folate respectively as serological markers for cognitive impairment diagnosis in patients with PD. Conclusion Serum Hcy and folate were different between PD-CI and PDN patients, which may play an important role in cognitive impairment development in patients with PD and can be used as promising serological diagnostic marker.

scholarly journals EFFECT OF HYDROALCOHOLIC EXTRACT OF ACHYRANTHES ASPERA ON HALOPERIDOLINDUCED PARKINSON’S DISEASE IN WISTAR RATS

2017 ◽  
Vol 10 (9) ◽  
pp. 318 ◽  
Author(s):  
Chitra V ◽  
Manasa K ◽  
Mythili A ◽  
Tamilanban T ◽  
Gayathri K
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
High Performance ◽  
Wistar Rats ◽  
Psychotic Disorders ◽  
Motor Coordination ◽  
Intraperitoneal Administration ◽  
Antioxidant Property ◽  
Electrochemical Detector ◽  
Achyranthes Aspera

  Objective: Prolonged usage of neuroleptics in psychotic disorders such as schizophrenia provokes extrapyramidal symptoms that are also seen in Parkinson’s disease. An attempt has been made to study the neuroprotective role of Achyranthes aspera hydroalcoholic (HA) extract on haloperidol-induced Parkinson’s symptoms in Wistar rats.Methods: The present study deals with the antiparkinson effect of HA extract of A. aspera on haloperidol (2 mg/kg intraperitoneal administration)- induced catatonia in Wistar rats. The motor coordination in case of haloperidol-treated animals was studied by performing rotarod test and hang test. Dopamine and 3,4-dihydroxyphenylacetic acid were estimated using an electrochemical detector and high-performance liquid chromatography. The antioxidant status was also assessed to know the neurotoxicity of haloperidol by estimating the levels of lipid peroxidation, superoxide dismutase, glutathione (GSH) peroxidase, and reduced GSH by performing individual assays.Results: All these assessments were done on 24 Wistar rats which were divided into four groups (n=6). HA was administered at 200 and 400 mg/kg doses, 30 minutes before haloperidol treatment for 20 days. HA significantly (*p<0.05, **p<0.01) improved the antioxidant status.Conclusion: The results shown that HA shows a protective role in haloperidol catalepsy and also possess antioxidant property.

scholarly journals The Contribution ofα-Synuclein Spreading to Parkinson’s Disease Synaptopathy

2017 ◽  
Vol 2017 ◽  
pp. 1-15 ◽  
Author(s):  
Francesca Longhena ◽  
Gaia Faustini ◽  
Cristina Missale ◽  
Marina Pizzi ◽  
PierFranco Spano ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neurodegenerative Disorders ◽  
Physiological Conditions ◽  
Age Related ◽  
Endogenous Protein ◽  
Synaptic Failure ◽  
Nigrostriatal Neurons ◽  
Somatic Nervous System ◽  
The Brain

Synaptopathies are diseases with synapse defects as shared pathogenic features, encompassing neurodegenerative disorders such as Parkinson’s disease (PD). In sporadic PD, the most common age-related neurodegenerative movement disorder, nigrostriatal dopaminergic deficits are responsible for the onset of motor symptoms that have been related toα-synuclein deposition at synaptic sites. Indeed,α-synuclein accumulation can impair synaptic dopamine release and induces the death of nigrostriatal neurons. While in physiological conditions the protein can interact with and modulate synaptic vesicle proteins and membranes, numerous experimental evidences have confirmed that its pathological aggregation can compromise correct neuronal functioning. In addition, recent findings indicate thatα-synuclein pathology spreads into the brain and can affect the peripheral autonomic and somatic nervous system. Indeed, monomeric, oligomeric, and fibrillaryα-synuclein can move from cell to cell and can trigger the aggregation of the endogenous protein in recipient neurons. This novel “prion-like” behavior could further contribute to synaptic failure in PD and other synucleinopathies. This review describes the major findings supporting the occurrence ofα-synuclein pathology propagation in PD and discusses how this phenomenon could induce or contribute to synaptic injury and degeneration.

scholarly journals Potential Metabolomic Linkage in Blood between Parkinson’s Disease and Traumatic Brain Injury

Metabolites ◽  
2018 ◽  
Vol 8 (3) ◽  
pp. 50 ◽  
Author(s):  
Massimo Fiandaca ◽  
Thomas Gross ◽  
Thomas Johnson ◽  
Michele Hu ◽  
Samuel Evetts ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Traumatic Brain Injury ◽  
Parkinson's Disease ◽  
Brain Injury ◽  
Glutamic Acid ◽  
High Performance ◽  
Specific Gene ◽  
Potential Association ◽  
Health And Disease ◽  
Mechanistic Basis

The etiologic basis for sporadic forms of neurodegenerative diseases has been elusive but likely represents the product of genetic predisposition and various environmental factors. Specific gene-environment interactions have become more salient owing, in part, to the elucidation of epigenetic mechanisms and their impact on health and disease. The linkage between traumatic brain injury (TBI) and Parkinson’s disease (PD) is one such association that currently lacks a mechanistic basis. Herein, we present preliminary blood-based metabolomic evidence in support of potential association between TBI and PD. Using untargeted and targeted high-performance liquid chromatography-mass spectrometry we identified metabolomic biomarker profiles in a cohort of symptomatic mild TBI (mTBI) subjects (n = 75) 3–12 months following injury (subacute) and TBI controls (n = 20), and a PD cohort with known PD (n = 20) or PD dementia (PDD) (n = 20) and PD controls (n = 20). Surprisingly, blood glutamic acid levels in both the subacute mTBI (increased) and PD/PDD (decreased) groups were notably altered from control levels. The observed changes in blood glutamic acid levels in mTBI and PD/PDD are discussed in relation to other metabolite profiling studies. Should our preliminary results be replicated in comparable metabolomic investigations of TBI and PD cohorts, they may contribute to an “excitotoxic” linkage between TBI and PD/PDD.

scholarly journals Cortical Visual Performance Test Setup for Parkinson’s Disease Based on Motion Blur Orientation

2019 ◽  
Vol 2019 ◽  
pp. 1-8
Author(s):  
M. Erdem Isenkul
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Visual Cortex ◽  
High Performance ◽  
Performance Test ◽  
Vertical Motion ◽  
Motion Blur ◽  
Visual Performance ◽  
Natural Image ◽  
Success Rates

Studies on Parkinson’s disease (PD) are becoming very popular on multidisciplinary platforms. The development of predictable telemonitored early detection models has become closely related to many different research areas. The aim of this article is to develop a visual performance test that can examine the effects of Parkinson’s disease on the visual cortex, which can be a subtitle scoring test in UPDRS. However, instead of showing random images and asking for discrepancies between them, it is expected that the questions to be asked to patients should be provable in the existing cortex models, should be deduced between the images, and produce a reference threshold value to compare with the practical results. In a developed test, horizontal and vertical motion blur orientation was applied to natural image samples, and then neural outputs were produced by representing three (original-horizontal-vertical) image groups with the Layer 4 (L4) cortex model. This image representation is then compared with a filtering model which is very similar to thalamus’ functionality. Thus, the linear problem-solving performance of the L4 cortex model is also addressed in the study. According to the obtained classification results, the L4 model produces high-performance success rates compared to the thalamic model, which shows the adaptation power of the visual cortex on the image pattern differences. In future studies, developed motion-based visual tests are planned to be applied to PD patient groups/controls, and their performances with mathematical threshold values will be examined.

scholarly journals Facile Impedimetric Analysis of Neuronal Exosome Markers in Parkinson’s Disease Diagnostics

2020 ◽  
Vol 92 (20) ◽  
pp. 13647-13651
Author(s):  
Ying Fu ◽  
Cheng Jiang ◽  
George K. Tofaris ◽  
Jason J. Davis
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Diagnostics
Sign in / Sign up

Export Citation Format

Share Document